Business Context and Reporting Period
Company: Can-Fite BioPharma Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Business Overview: Can-Fite is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics targeting the A3 adenosine receptor (A3AR) for autoimmune-inflammatory, oncological, and ophthalmic diseases. The company has no commercial products and generates revenue primarily through out-licensing agreements. Key product candidates include CF101 (autoimmune/ophthalmic), CF102 (oncology/hepatitis), and CF602 (inflammatory/sexual dysfunction).
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric | 2014 (NIS '000s) | 2014 (USD '000s) | 2013 (NIS '000s) |
|---|---|---|---|
| Revenues | 0 | 0 | 0 |
| Research & Development Expenses | 16,200 | 4,165 | 15,390 |
| General & Administrative Expenses | 11,573 | 2,976 | 15,922 |
| Operating Loss | (27,773) | (7,141) | (31,312) |
| Net Loss | (24,524) | (6,306) | (30,812) |
| Cash and Cash Equivalents (End of Period) | 36,091 | 9,280 | 20,767 |
| Total Assets | 39,667 | 10,200 | 23,105 |
| Total Liabilities | 12,967 | 3,335 | 7,580 |
| Shareholders' Equity | 26,700 | 6,865 | 15,525 |
Note: USD conversions are based on the exchange rate of NIS 3.889 to $1.00 as of December 31, 2014.
Material Changes vs. Prior Period
- Revenue: The company reported zero revenue for 2014, consistent with 2013. Historically, revenue has been derived from licensing agreements (Seikagaku and Kwang Dong), but no milestone or royalty payments were recognized in 2014.
- Operating Loss: Operating loss decreased by approximately 11.3% (NIS 3.5 million) compared to 2013, primarily driven by a significant reduction in General and Administrative (G&A) expenses.
- Expenses:
- R&D: Increased by 5.3% (NIS 0.81 million) due to higher clinical trial costs.
- G&A: Decreased by 27.3% (NIS 4.35 million) due to lower investor relations expenses, share-based payments, salaries, and professional fees.
- Liquidity: Cash and cash equivalents increased by 73.6% (NIS 15.3 million) year-over-year, bolstered by capital raising activities in 2014.
- Capital Raising: In 2014, the company raised approximately $13 million through a private placement ($5 million) in March and an at-the-market registered direct offering ($8 million) in December.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Cash Runway: Management believes existing financial resources (approx. $9.3 million as of Dec 31, 2014) are sufficient to meet requirements for the next twelve months.
- Future Funding: The company anticipates incurring substantial operating losses for the foreseeable future and will require additional capital to fund clinical trials and commercialization. Future funding may come from equity/debt financings, strategic partnerships, or licensing arrangements.
- Clinical Milestones:
- CF101 (Psoriasis): Top-line results from a Phase II/III trial expected in late March 2015.
- CF101 (RA): Preparing for a Phase III trial.
- CF102 (HCC): Conducting a Phase II study; patient enrollment expected by end of 2015.
- CF101 (Ophthalmic): OphthaliX (subsidiary) conducting Phase II trials for glaucoma and initiating studies for uveitis.
Risks and Contingencies
- Clinical Trial Failure: The company faces significant risk of failure in clinical trials. Notably, a Phase III study for Dry Eye Syndrome (DES) failed to meet primary endpoints in late 2013, leading to the discontinuation of that indication. Two Phase IIb studies for Rheumatoid Arthritis (RA) in combination with methotrexate also failed primary endpoints, though a subsequent monotherapy study met endpoints.
- Patent Expiration: Composition of matter patents for CF101 and CF102 licensed from the NIH expired in Europe (July 2014) and are set to expire in the U.S. (June 2015). The license agreement with the NIH terminates on June 30, 2015. The company relies on use patents and potential data exclusivity for protection.
- Financial Position: The company has an accumulated deficit of approximately NIS 304 million. It has never been profitable and expects to continue incurring losses.
- Regulatory and Political: Operations are based in Israel, exposing the company to regional political and military instability. Additionally, regulatory approval processes (FDA, EMA) are lengthy, costly, and uncertain.
Key Facts for Investor Verification
- Cash Position: Verify the current cash balance and burn rate to confirm the "12-month runway" assertion, especially given the lack of revenue.
- Psoriasis Trial Results: Monitor the release of top-line results for the CF101 Phase II/III psoriasis trial (expected March 2015), as this is a critical near-term catalyst.
- NIH License Status: Confirm the status of the NIH license agreement expiring June 30, 2015, and the company's strategy to maintain IP protection post-expiration.
- OphthaliX Subsidiary: Review the financial health and funding status of OphthaliX Inc. (82% owned), including the deferred payments owed to Can-Fite (approx. $2.46 million as of Dec 31, 2014) and the financial support letter issued in March 2015.
- Capital Requirements: Assess the likelihood and terms of future capital raises, as the company explicitly states it will need additional funds to continue operations beyond the next 12 months.